FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896426822> ?p ?o ?g. }

• W2896426822 abstract "Abstract The 2018 NIA-AA research framework proposes a classification system with beta- A myloid deposition, pathologic T au, and n eurodegeneration (ATN) for the diagnosis and staging of Alzheimer’s Disease (AD). Data from the ADNI (AD neuroimaging initiative) database can be utilized to identify diagnostic signatures for predicting AD progression, and to determine the utility of this NIA-AA research framework. Profiles of 320 peptides from baseline cerebrospinal fluid (CSF) samples of 287 normal, mild cognitive impairment (MCI) and AD subjects followed over a 3-10 year period were measured via multiple reaction monitoring (MRM) mass spectrometry. CSF Aβ 42 , total-Tau (tTau), phosphorylated-Tau (pTau-181) and hippocampal volume were also measured. From these candidate markers, optimal diagnostic signatures with decision thresholds to separate AD and normal subjects were first identified via unbiased regression and tree-based algorithms. The best performing signature determined via cross-validation was then tested in an independent group of MCI subjects to predict future progression. This multivariate analysis yielded a simple diagnostic signature comprising CSF pTau-181 to Aβ 42 ratio, MRI hippocampal volume and a novel PTPRN peptide, with a decision threshold on each marker. When applied to a separate MCI group at baseline, subjects meeting this signature criteria experience 4.3-fold faster progression to AD compared to a 2.2-fold faster progression using only conventional markers. This novel 4-marker signature represents an advance over the current diagnostics based on widely used marker, and is much easier to use in practice than recently published complex signatures. In addition, this signature reinforces the ATN construct from the 2018 NIA-AA research framework. Disclosures Viswanath Devanarayan is an employee of Charles River Laboratories, and as such owns equity in, receives salary and other compensation from Charles River Laboratories. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.;Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California." @default.
• W2896426822 created "2018-10-26" @default.
• W2896426822 creator A5041938256 @default.
• W2896426822 creator A5060781519 @default.
• W2896426822 creator A5084270388 @default.
• W2896426822 date "2018-10-15" @default.
• W2896426822 modified "2023-09-25" @default.
• W2896426822 title "Identification of a simple and novel cut-point based CSF and MRI signature for predicting Alzheimer’s disease progression that reinforces the 2018 NIA-AA research framework" @default.
• W2896426822 cites W1543788907 @default.
• W2896426822 cites W1919599643 @default.
• W2896426822 cites W1966159727 @default.
• W2896426822 cites W1968352263 @default.
• W2896426822 cites W1973110960 @default.
• W2896426822 cites W1980314710 @default.
• W2896426822 cites W2006995834 @default.
• W2896426822 cites W2008301592 @default.
• W2896426822 cites W2012034410 @default.
• W2896426822 cites W2021560851 @default.
• W2896426822 cites W2027937356 @default.
• W2896426822 cites W2036362108 @default.
• W2896426822 cites W2055925643 @default.
• W2896426822 cites W2061699647 @default.
• W2896426822 cites W2065388283 @default.
• W2896426822 cites W2083106796 @default.
• W2896426822 cites W2084397926 @default.
• W2896426822 cites W2084979315 @default.
• W2896426822 cites W2088084445 @default.
• W2896426822 cites W2090221075 @default.
• W2896426822 cites W2094058326 @default.
• W2896426822 cites W2109527205 @default.
• W2896426822 cites W2110437310 @default.
• W2896426822 cites W2113319997 @default.
• W2896426822 cites W2122130235 @default.
• W2896426822 cites W2139214514 @default.
• W2896426822 cites W2149502850 @default.
• W2896426822 cites W2151721316 @default.
• W2896426822 cites W2159122349 @default.
• W2896426822 cites W2163057869 @default.
• W2896426822 cites W2168283959 @default.
• W2896426822 cites W2295393683 @default.
• W2896426822 cites W2473313434 @default.
• W2896426822 cites W2515127987 @default.
• W2896426822 cites W2585846175 @default.
• W2896426822 cites W2593927122 @default.
• W2896426822 cites W2744722702 @default.
• W2896426822 cites W2762301636 @default.
• W2896426822 cites W2781544338 @default.
• W2896426822 cites W2795678519 @default.
• W2896426822 cites W2798054687 @default.
• W2896426822 cites W2802659348 @default.
• W2896426822 cites W3106889297 @default.
• W2896426822 cites W4294541781 @default.
• W2896426822 cites W1971424020 @default.
• W2896426822 doi "https://doi.org/10.1101/443325" @default.
• W2896426822 hasPublicationYear "2018" @default.
• W2896426822 type Work @default.
• W2896426822 sameAs 2896426822 @default.
• W2896426822 citedByCount "1" @default.
• W2896426822 countsByYear W28964268222019 @default.
• W2896426822 crossrefType "posted-content" @default.
• W2896426822 hasAuthorship W2896426822A5041938256 @default.
• W2896426822 hasAuthorship W2896426822A5060781519 @default.
• W2896426822 hasAuthorship W2896426822A5084270388 @default.
• W2896426822 hasBestOaLocation W28964268221 @default.
• W2896426822 hasConcept C105795698 @default.
• W2896426822 hasConcept C119857082 @default.
• W2896426822 hasConcept C126322002 @default.
• W2896426822 hasConcept C142724271 @default.
• W2896426822 hasConcept C143998085 @default.
• W2896426822 hasConcept C15744967 @default.
• W2896426822 hasConcept C161584116 @default.
• W2896426822 hasConcept C169760540 @default.
• W2896426822 hasConcept C2778373026 @default.
• W2896426822 hasConcept C2779134260 @default.
• W2896426822 hasConcept C2779651940 @default.
• W2896426822 hasConcept C2781415353 @default.
• W2896426822 hasConcept C2984915365 @default.
• W2896426822 hasConcept C33923547 @default.
• W2896426822 hasConcept C41008148 @default.
• W2896426822 hasConcept C58693492 @default.
• W2896426822 hasConcept C71924100 @default.
• W2896426822 hasConceptScore W2896426822C105795698 @default.
• W2896426822 hasConceptScore W2896426822C119857082 @default.
• W2896426822 hasConceptScore W2896426822C126322002 @default.
• W2896426822 hasConceptScore W2896426822C142724271 @default.
• W2896426822 hasConceptScore W2896426822C143998085 @default.
• W2896426822 hasConceptScore W2896426822C15744967 @default.
• W2896426822 hasConceptScore W2896426822C161584116 @default.
• W2896426822 hasConceptScore W2896426822C169760540 @default.
• W2896426822 hasConceptScore W2896426822C2778373026 @default.
• W2896426822 hasConceptScore W2896426822C2779134260 @default.
• W2896426822 hasConceptScore W2896426822C2779651940 @default.
• W2896426822 hasConceptScore W2896426822C2781415353 @default.
• W2896426822 hasConceptScore W2896426822C2984915365 @default.
• W2896426822 hasConceptScore W2896426822C33923547 @default.
• W2896426822 hasConceptScore W2896426822C41008148 @default.
• W2896426822 hasConceptScore W2896426822C58693492 @default.
• W2896426822 hasConceptScore W2896426822C71924100 @default.
• W2896426822 hasLocation W28964268221 @default.
• W2896426822 hasOpenAccess W2896426822 @default.

• next